Figure 5 from the Proteogenomics of Prostate Cancer Radioresistance

Roni Haas, Gavin Frame,Shahbaz Khan,Beth K. Neilsen, Boon Hao Hong, Celestia P.X. Yeo, Takafumi N. Yamaguchi,Enya H.W. Ong, Wenyan Zhao, Benjamin Carlin, Eugenia L.L. Yeo, Kah Min Tan, Yuan Zhe Bugh, Chenghao Zhu,Rupert Hugh-White,Julie Livingstone,Dennis J.J. Poon,Pek Lim Chu,Yash Patel, Shu Tao,Vladimir Ignatchenko,Natalie J. Kurganovs, Geoff S. Higgins,Michelle R. Downes,Andrew Loblaw,Danny Vesprini, Amar U. Kishan,Melvin L.K. Chua, Thomas Kislinger,Paul C. Boutros,Stanley K. Liu

crossref(2024)

引用 0|浏览0
暂无评分
摘要
The proteome signature upon POLQ inhibition. A, Experimental design schematic. B, Genetic POLQ inhibition. The parental, CF-resistant, and HF-resistant cells were treated with either POLQ siRNA or scramble siRNA as the control. Significant radiosensitization was observed in all cell lines upon POLQ knockdown (P = 0.01, 0.002, and 0.02 for the parental, CF-resistant, and HF-resistant cells, respectively; paired t test). Three biological replicas of 4,000 cells per well and three of 6,000 cells per well were considered for each sample. C, Pharmacologic POLQ inhibition. CF-resistant, HF-resistant, and the parental cells were treated with 100 μmol/L novobiocin to achieve POLQ inhibition (Nvb 100 µmol/L). Significant radiosensitization was observed in all DU145 cell lines upon POLQ inhibition (P = 0.04, 0.02 and 0.01, for the parental, CF-resistant, and HF-resistant cells; paired t test). In B and C, both the control and the treated cells were irradiated with 0 or 4 Gy in two fractions. The surviving fraction of the treated cells (POLQ siRNA or Nvb 100 µmol/L) was normalized to the surviving fraction of the corresponding control of each cell line (black dots). D, The (top) 10 activated and suppressed biological processes at the protein level following POLQ depletion, in CF-resistant cells and the parental. The dot size represents the enrichment score, and the dot color is the directionality: orange shows upregulation toward POLQ-treated cells. E,POLQ genetic inhibition creates a proteomic signature, involving 12 affected genes in CF-resistant cells. Three replicates from each cell type were used for the analysis. Left: signature genes whose protein abundances were changed between POLQ-depleted cells and the control, in CF-resistant cells and the parental cells. The dot size represents the Cohen’s d effect size, and the dot color is the directionality: magenta, upregulation, and green, downregulation toward POLQ-treated cells. Middle: changes in protein abundances of signature genes, between CF-resistant cells and the parental. The dot size represents the Cohen’s d effect size, and the dot color is the directionality: magenta, upregulation, and green, downregulation toward CF-resistant cells. Right: changes in RNA abundances of signature genes between CF-resistant cells and the parental. The dot size represents the log2 (fold change) values. The dot color represents the directionality: red shows upregulation toward CF-resistant cells. F, Investigating signature genes (that were affected by POLQ inhibition in cell lines) in primary patient data. Left: RNA-RNA Pearson correlations between POLQ and signature genes. Middle, Pearson correlation between the abundances of POLQ RNA and proteins of signature genes. Right: Abundance of signature genes in normal vs. tumor samples at the RNA and protein levels. For all panels, datasets refer to the cohort names used for analysis and the data type for the type of molecule tested for signature genes (i.e., RNA or protein).
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要